Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

53 results
Display

Extensive Nevus Comedonicus with Inflammatory Nodules and Cysts Controlled with Adalimumab

Lee EH, Lee SH, Sohng C, Kim JY, Park KD, Lee SJ, Lee WJ

Nevus comedonicus is a very rare skin disorder characterized by the presence of comedo-like dilated pores with keratinous plugs, rarely resulting in painful recurrent inflammatory nodules or cysts. It presents...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease

Kim JY, Lee Y, Choe BH, Kang B

Background/Aims: Anti-drug antibodies (ADAs) can develop during treatment with anti-tumor necrosis factor (TNF) agents. We aimed to investigate the factors associated with immunogenicity of anti-TNF agents in pediatric patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is adalimumab safe and effective in patients with intestinal Behcet’s disease in real-world practice?

Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T

Background/Aims: The safety and effectiveness of adalimumab was demonstrated in a phase 3 trial in Japanese patients with intestinal Behçet’s disease. The aim of this study was to evaluate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pustular Eruption Induced by Adalimumab in a Patient with Ankylosing Spondylitis: A Case Report

Lim JH, Kwon SH, Sim WY, Lew BL

  • KMID: 2517082
  • Korean J Dermatol.
  • 2021 Jun;59(5):394-397.
Many cutaneous adverse reactions including eczematoid dermatitis and lichenoid eruption have been reported with the increased usage of tumor necrosis factor-α inhibitors. However, there are very few reports of generalized...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea

Lee Ms, Lee CH, Lee HS, Sung YK, Choi JR, Park K, Lim MK, Choi BY, Kim HA, Choi SW, Lee Y, Yoo WH

Objective: Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disorder that impairs patients’ overall health-related quality of life (HRQOL). In this study, we evaluated the effect of adalimumab in Korean...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis

Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH

Background/Aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no headto-head comparison of treatment efficacy and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report

Oh JH, Ham SP, Park HJ

Recently, biologic therapy has become a major advance in the management of moderate-to-severe psoriasis. Although the overall safety profile of biologics is favorable, primary infection or reactivation of latent tuberculosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis

Park SE, Jun JW, Lee DH, Lee SC, Kim M

We sought to analyze the efficacy of adalimumab in active noninfectious uveitis, and evaluate its efficacy and safety for the management of refractory noninfectious uveitis in Korean patients. A retrospective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease

Jung YS, Han M, Park S, Cheon JH

Background/Aims: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with Crohn’s disease (CD) are rare, particularly for Asian patients. We compared the key clinical outcomes...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis

Choe S, Heo JW, Oh BL

Purpose: To evaluate the effect of adalimumab in pediatric uveitis and subsequent changes in anterior chamber inflammation following the inactivation of uveitis. Methods: In this retrospective study, patients with noninfectious uveitis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Adalimumab on Refractory Uveitis

Lee SH, Yoo YS, Oh HS

Purpose: To assess the efficacy and safety of Adalimumab (Humira®, AbbVie, Chicago, IL, USA) for repeated refractory uveitis during systemic steroid or immunosuppressive therapy. Methods: We retrospectively reviewed clinical records on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study

Oh EH, Kim J, Ham N, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD

Background/Aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking. Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Potential Utility of Therapeutic DrugMonitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients

Choi SY, Choi YO, Choe YH, Kang B

Background: Limited data exist regarding mucosal healing (MH) and therapeutic drug monitoring (TDM) in pediatric Crohn's disease (CD) patients treated with adalimumab (ADL). We aimed to investigate the associations between...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies

van Rheenen H, van Rheenen PF

PURPOSE: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study

Han M, Jung YS, Cheon JH, Park S

PURPOSE: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with ulcerative colitis (UC) are extremely limited, especially in the Asian population. We compared clinically important...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia G, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu , Yang SK, Ouyang Q, Geary R, De Silva J, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW, on behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis

The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of severe hidradenitis suppurativa with biologic therapy and wide excision

Lim SY, Cheong EC, Oon HH

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis

Lee S, Park YJ, Lee JY

BACKGROUND: Tumor necrosis factor-alpha (TNF-α) inhibitors (TNFis), which are the main treatment for ankylosing spondylitis (AS), have been reported not only to reduce the incidence of anterior uveitis (AU) but...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies

Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T

BACKGROUND/AIMS: Few reports have described the long-term treatment outcomes of the anti-tumor necrosis factor-α antibody for Japanese Crohn’s disease (CD) patients. The aim of this study was to evaluate them...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Paradoxical Flare of Pustular Psoriasis after Ustekinumab Therapy

Kang IH, Shin MK, Lee MH, Jeong KH

  • KMID: 2436996
  • Korean J Dermatol.
  • 2018 Nov;56(9):548-551.
Biologics are the most advanced treatment for psoriasis. Ustekinumab, one of the biologics for psoriasis, is a human monoclonal antibody that binds to the p40 subunit of interleukin-12 and interleukin-23....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr